Mindstate Design Labs
Mindstate Design Labs, formerly known as Kykeon Biotechnologies, is a healthcare company specializing in the development of psychedelic therapeutics for mental health, utilizing AI and machine learning.
Services
Mindstate Design Labs focuses on developing the next generation of psychedelic therapeutics for mental health indications. The company designs novel altered states of consciousness using machine learning, human experiential data, and molecular pharmacology. Their pipeline involves a combination approach using psychedelic 'primer' compounds with non-psychedelic 'probe' compounds to create potent therapeutic interventions. To date, they have identified six probe candidates with potentially unique therapeutic utility when combined with their lead primer.
Founders
Mindstate Design Labs, previously known as Kykeon Biotechnologies Inc., and Kykeon Biotechnologies, is driven by a team of seven individuals. The company's focus is on harnessing modern technology to tackle mental health challenges through the innovative use of psychedelic therapeutics.
Locations
Mindstate Design Labs operates out of two primary locations in the United States: San Francisco, CA, and Pittsburgh, PA. These hubs facilitate their research and development efforts in the mental health and drug discovery sector. The company also adopts a flexible working model, offering remote and partly remote opportunities to accommodate their geographically dispersed team.
History
Mindstate Design Labs is an early-stage company and a participant in Y Combinator's S21 batch. The company, initially known as Kykeon Biotechnologies Inc., was previously referred to as Kykeon Biotechnologies. Their journey through Y Combinator underscores their innovative approach in the healthcare and drug discovery sectors. They are leveraging artificial intelligence and machine learning to pioneer the development of psychedelic therapeutics for mental health.
Osmanthus Target Discovery Platform
Mindstate Design Labs has developed Osmanthus, a target discovery and phenotypic screening platform dedicated to altered conscious states. Osmanthus integrates machine learning, molecular pharmacology, and human experiential data to identify and explore compounds that induce specific altered states of consciousness. This platform is central to their strategy in identifying and developing new therapeutics.
